


## CD79a Antibody [clone IGA/764] (V3038)


Catalog No.	Formulation	Size
V3038-100UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	100 ug
V3038-20UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	20 ug
V3038SAF-100UG	1 mg/ml in 1X PBS; BSA free, sodium azide free	100 ug
V3038IHC-7ML	Prediluted in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide; *For IHC use only*	7 ml

**Bulk quote request**


<b>Availability</b>	1-3 business days
<b>Species Reactivity</b>	Human
<b>Format</b>	Purified
<b>Clonality</b>	Monoclonal (mouse origin)
<b>Isotype</b>	Mouse IgG1, kappa
<b>Clone Name</b>	IGA/764
<b>Purity</b>	Protein G affinity chromatography
<b>UniProt</b>	P11912
<b>Localization</b>	Cell surface, cytoplasmic
<b>Applications</b>	Immunofluorescence : 1-2ug/ml Western Blot : 1-2ug/ml Immunohistochemistry (FFPE) : 1-2ug/ml for 30 min at RT
<b>Limitations</b>	This CD79a antibody is available for research use only.



IHC: Formalin-fixed, paraffin-embedded human lymphoma stained with CD79a antibody (clone IGA/764).



Immunofluorescent staining of PFA-fixed human Raji cells with CD79a antibody (green, clone IGA/764) and Reddot nuclear stain (red).



Western blot testing of human Raji cell lysate with CD79a antibody (clone IGA/764). Expected molecular weight: 25-47 kDa depending on glycosylation level.

## Description

A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with RituximAb (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.

## Application Notes

Optimal dilution of the CD79a antibody should be determined by the researcher.

1. Staining of formalin-fixed tissues requires boiling tissue sections in pH 9 10mM Tris with 1mM EDTA for 10-20 min followed by cooling at RT for 20 min.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

## Immunogen

Recombinant human protein was used as the immunogen for the CD79a antibody.

## Storage

Store the CD79a antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

